ProtaGene ads

Comparability is often discussed as an analytical exercise. In reality, it starts much earlier. It begins with understanding the manufacturing change, assessing potential risks and selecting the analytical approach that can answer the right scientific questions. Our upcoming webinar with @André Abts provides practical insights into these decisions through real examples from analytical comparability and biosimilar projects. Looking forward to seeing many of you there. LIVE Webinar: Wednesday, September 9th 2026 - 4:00 PM CEST / 10:00 AM EST A valuable session for anyone involved in biologics development or analytics.

One of the most interesting aspects of biologics development is that manufacturing changes are often unavoidable. The real challenge is demonstrating that these changes do not affect the product in a clinically meaningful way. Our upcoming webinar explores exactly that. LIVE Webinar: Wednesday, September 9th 2026 - 4:00 PM CEST

Manufacturing processes evolve. Facilities change. Processes are optimized. Scale increases. But every change raises the same fundamental question: Can you demonstrate that your product remains comparable? Analytical comparability is far more than generating data. It starts with a risk-based strategy, selecting the right samples, defining an appropriate analytical panel and understanding which data are needed to support regulatory decisions. In our upcoming webinar, “Analytical Comparability of Biologics: From Protein Characterization to Structure–Function Insight”, André Abts will discuss: • When a comparability study becomes necessary • How to build a scientifically justified comparability strategy • Practical case studies from analytical comparability and biosimilar projects Join us to learn how thoughtful analytical characterization can reduce uncertainty and strengthen your comparability package. 📅 September 9th, 4:00-4:45 PM CET / 10:00-10:45 AM EST 🎙️ Live webinar

Whether introducing a new manufacturing site, modifying a process or implementing post-approval changes, demonstrating comparability is essential to maintaining confidence in product quality, safety and efficacy. A successful comparability exercise is not defined by the number of analytical methods used but by selecting the right strategy for the specific change and understanding the potential impact before testing begins. 📅 September 9th, 4:00-4:45 PM CET / 10:00-10:45 AM EST 🎙️ Live webinar If comparability is part of your development or lifecycle management, this session is designed for you.

Host Cell Proteins remain one of the most critical quality and safety considerations in biopharmaceutical manufacturing. Yet the actual coverage of anti-HCP antibodies used in ELISA assays is often incomplete and can vary significantly depending on immunogen and antibody production processes. What happens to HCPs that remain undetected? 📅 June 24, 4:00-4:45 PM CET 🎙️ Live webinar Join us to learn how advanced mass spectrometry-based approaches can support more robust and reliable HCP monitoring strategies.

Not all HCPs are equally visible in ELISA assays. And that can become a critical challenge for biopharmaceutical development and quality control. In our upcoming webinar, @Dr. Daniel Waldera-Lupa will discuss how quantitative IAC-MS can help evaluate antibody reagent coverage in ELISA assays and uncover hidden detection gaps that may otherwise remain unnoticed. The webinar builds on ProtaGene’s work in advancing mass spectrometry-based HCP analysis and also connects directly to our published research in this field. As part of the webinar invitation, we also encourage you to explore our publication on HCP-MS for ELISA antibody coverage determination. Webinar: HCP Detection Gap Risk Mitigation: Quantitative IAC-MS for ELISA Antibody Reagent Coverage Determination on June 24, 4 PM CEST